OncoMatch/Clinical Trials/NCT06522737
A Study of Duvelisib Versus Gemcitabine or Bendamustine in Participants With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) Phenotype
Is NCT06522737 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies multiple treatments including Duvelisib and Gemcitabine for lymphoma.
Treatment: Duvelisib · Gemcitabine · Bendamustine — The study will evaluate the progression-free survival benefit of duvelisib monotherapy as compared to investigator's choice of gemcitabine or bendamustine in participants with relapsed/refractory nodal T cell lymphoma with TFH phenotype.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Other
Cancer type
Non-Hodgkin Lymphoma
Hodgkin Lymphoma
Prior therapy
Must have received: cytotoxic chemotherapy
Relapsed or refractory to at least 1 prior systemic, cytotoxic therapy for T cell lymphoma.
Cannot have received: phosphoinositide-3-kinase (PI3K) inhibitor
Received prior treatment with a phosphoinositide-3-kinase (PI3K) inhibitor.
Cannot have received: allogeneic transplant
Received prior allogeneic transplant any time in the past
Cannot have received: autologous transplant
Exception: within 60 days prior to the first dose of study drug
received autologous transplant within 60 days prior to the first dose of study drug
Cannot have received: gemcitabine (gemcitabine)
Exception: within 60 days prior to the first dose of study drug
Prior exposure to planned study treatment investigator's choice therapy (gemcitabine or bendamustine) within 60 days prior to the first dose of study drug.
Cannot have received: bendamustine (bendamustine)
Exception: within 60 days prior to the first dose of study drug
Prior exposure to planned study treatment investigator's choice therapy (gemcitabine or bendamustine) within 60 days prior to the first dose of study drug.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06522737 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior phosphoinositide-3-kinase (PI3K) inhibitor, allogeneic transplant, autologous transplant disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages